Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Servier And Ideaya Biosciences Announced An Exclusive License Agreement For Darovasertib For Rare Eye Cancer, Servier Obtains Rights For Darovasertib Outside US, Ideaya Will Receive An Upfront Payment Of $210M And Up To $320 Million In Milestones, Plus Sales-based Royalties

Author: Benzinga Newsdesk | September 02, 2025 06:05am

Servier and IDEAYA Biosciences enter into an exclusive license agreement for regulatory and commercial rights to darovasertib outside the US
Darovasertib is a small molecule developed for patients with uveal melanoma, a rare type of eye cancer with high unmet medical need
IDEAYA will receive an upfront payment of $210 million and up to $320 million in regulatory and commercial milestones, plus double-digit royalties on net sales
IDEAYA and Servier will collaborate on the development of darovasertib and share the associated costs

Posted In: IDYA